Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

Clinical Therapeutics

Volumn 38, Issue 6, 2016, Pages 1299-1313

  Kohler, Sven ^a   Salsali, Afshin ^b   Hantel, Stefan ^a   Kaspers, Stefan ^a   Woerle, Hans J ^a   Kim, Gabriel ^a   Broedl, Uli C ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

adverse drug event; hypoglycemia; ketoacidosis; safety; SGLT2 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ELECTROLYTE; EMPAGLIFLOZIN; LIPID; PARATHYROID HORMONE; PLACEBO; URIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLADDER CANCER; BREAST CANCER; BRONCHITIS; COUGHING; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; HEADACHE; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; KIDNEY CANCER; KIDNEY DYSFUNCTION; LIMB PAIN; LIVER INJURY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; INCIDENCE; META ANALYSIS; URINARY TRACT INFECTIONS;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY TRACT INFECTIONS;

EID: 84964334442     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.031     Document Type: Article

References (44)

1. R. Grempler, L. Thomas, M. Eckhardt, and et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 83 2012 83 90
2. L.A. Gallo, E.M. Wright, and V. Vallon Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences Diab Vasc Dis Res 12 78 2015 78 89
3. H.U. Haering, L. Merker, E. Seewaldt-Becker, and et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 3396 2013 3396 3404
4. M. Roden, J. Weng, J. Eilbracht, and et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol 1 208 2013 208 219
5. H.U. Haering, L. Merker, E. Seewaldt-Becker, and et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 1650 2014 1650 1659
6. C.S. Kovacs, V. Seshiah, R. Swallow, and et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 16 147 2014 147 158
7. J. Rosenstock, A. Jelaska, G. Frappin, and et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 37 1815 2014 1815 1823
8. I. Tikkanen, K. Narko, C. Zeller, and et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes Care 38 420 2015 420 428
9. J. Rosenstock, A. Jelaska, C. Zeller, and et al. Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 17 2015 936 948
10. FDA guidance: reviewer guidance conducting a clinical safety review of a new product application and preparing a report on the review. February 2005. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072974.pdf. Last accessed March 23, 2015.
11. E. Ferrannini, L. Seman, E. Seewaldt-Becker, and et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 15 721 2013 721 728
12. T. Heise, L. Seman, S. Macha, and et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus Diabetes Ther 4 331 2013 331 345
13. T. Heise, E. Seewaldt-Becker, S. Macha, and et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes Diabetes Obes Metab 15 613 2013 613 621
14. S. Kanada, K. Koiwai, A. Taniguchi, and et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus J Diabetes Investig 4 613 2013 613 617
15. J. Rosenstock, L.J. Seman, A. Jelaska, and et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes Metab 15 1154 2013 1154 1160
16. A.H. Barnett, A. Mithal, J. Manassie, and et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2 369 2014 369 384
17. T. Kadowaki, M. Haneda, N. Inagaki, and et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial Adv Ther 31 621 2014 621 638
18. M. Ridderstråle, K.R. Andersen, C. Zeller, and et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial Lancet Diabetes Endocrinol 2 691 2014 691 700
19. X. Zhao, Y. Cui, S. Zhao, and et al. Pharmacokinetics and pharmacodynamic properties and tolerability of single- and multiple-dose once-daily empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Chinese patients with type 2 diabetes Clin Ther 37 1493 2015 1493 1502
20. E. Ferrannini, A. Berk, S. Hantel, and et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 36 4015 2013 4015 4021
21. T. Kadowaki, M. Haneda, N. Inagaki, and et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study Adv Ther 32 306 2015 306 318
22. H.U. Haering, L. Merker, A.V. Christiansen, and et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes Diabetes Res Clin Pract 110 2015 82 90
23. C.S. Kovacs, V. Seshiah, L. Merker, and et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes Clin Ther 37 1773 2015 1773 1788
24. L. Merker, H.U. Haering, A.V. Christiansen, and et al. Empagliflozin as add-on to metformin in people with type 2 diabetes Diabet Med 32 2015 1555 1567
25. M. Roden, L. Merker, A.V. Christiansen, and et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial Cardiovasc Diabetol 14 2015 154
26. B. Zinman, C. Wanner, J.M. Lachin, and et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2015 2117 2128
27. A. Ptaszynska, K.M. Johnsson, S.J. Parikh, and et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events Drug Saf 37 815 2014 815 829
28. X.P. Yang, D. Lai, X.Y. Zhong, and et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis Eur J Clin Pharmacol 70 1149 2014 1149 1158
29. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34:S279-S284.
30. A.J. Scheen Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes Expert Opin Drug Saf 14 505 2015 505 524
31. Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) US Prescribing Information; 2014.
32. K.M. Johnsson, A. Ptaszynska, B. Schmitz, and et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 27 479 2013 479 484
33. M. Rosiak, S. Grzeszczak, D.A. Kosior, and M. Postuła Emerging treatments in type 2 diabetes: focus on canagliflozin Ther Clin Risk Manag 10 683 2014 683 689
34. D.Z. Cherney, B.A. Perkins, N. Soleymanlou, and et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 587 2014 587 597
35. M. Skrtić, G.K. Yang, B.A. Perkins, and et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration Diabetologia 57 2599 2014 2599 2602
36. D. Vasilakou, T. Karagiannis, E. Athanasiadou, and et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 159 262 2013 262 274
37. E. Ferrannini, E. Muscelli, S. Frascerra, and et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 124 2014 499 508
38. S.I. Taylor, J.E. Blau, and K.I. Rother SGLT2 inhibitors may predispose to ketoacidosis J Clin Endocrinol Metab 100 2849 2015 2849 2852
39. S. Halimi, and B. Vergès Adverse effects and safety of SGLT-2 inhibitors Diabetes Metab 40 S28 2014 S28 S34
40. S.S. Lund, N. Sattar, A. Salsali, and et al. Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes Diabetologia 58 2015 S360
41. J. Blaine, M. Chonchol, and M. Levi Renal control of calcium, phosphate, and magnesium homeostasis Clin J Am Soc Nephrol 10 2014 1257 1272
42. Janssen Pharmaceuticals Inc. Invokana (canagliflozin) US Prescribing Information; 2014.
43. M. Doblado, and K.H. Moley Facilitative glucose transporter 9, a unique hexose and urate transporter Am J Physiol Endocrinol Metab 297 E831 2009 E831 E835
44. Y. Chino, Y. Samukawa, S. Sakai, and et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria Biopharm Drug Dispos 35 391 2014 391 404